Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications.
about
Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus.Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.Introduction of biosimilar insulins in Europe.Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review.
P2860
Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Interchangeability among refer ...... ign and clinical implications.
@en
type
label
Interchangeability among refer ...... ign and clinical implications.
@en
prefLabel
Interchangeability among refer ...... ign and clinical implications.
@en
P2093
P2860
P356
P1476
Interchangeability among refer ...... sign and clinical implications
@en
P2093
H A Dowlat
M K Kuhlmann
P2860
P304
P356
10.1111/DOM.12676
P50
P577
2016-05-20T00:00:00Z